Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04944121 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of RSLV-132 in Subjects With Long COVID
A Phase 2 study, sponsored by Resolve Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
NCT04944121: Completed Phase 2 study, sponsored by Resolve Therapeutics.
NCT04944121 is a Phase 2 study that has completed, run by Resolve Therapeutics. The registered enrollment target is 112 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (16% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04944121, a Phase 2 study, has completed, sponsored by Resolve Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy (decrease in profound fatigue), safety and pharmacokinetics of RSLV-132 in subjects with long Corona Virus (COVID) syndome
Primary Outcome
Mean change in Patient-Reported Outcomes Measurement Information System Fatigue Short Form 7a (PROMIS Fatigue 7a) T-score at the end of treatment compared to baseline. The PROMIS Fatigue 7a consists of seven questions measuring symptoms severity at five-point intervals, with higher scores representing a worse outcome.
Interventions
- DRUG RSLV-132
- DRUG Sodium Chloride 0.9%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2021-06-25 |
| Est. Completion | 2023-11-30 |
| Phase | Phase 2 |
What the finished NCT04944121 record still lists
NCT04944121 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (16% lower).
The record links to 0 conditions, and to 2 interventions - of which RSLV-132 is the first listed.
NCT04944121 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04944121 about?
NCT04944121 is a clinical study titled "Phase 2 Study of RSLV-132 in Subjects With Long COVID". The purpose of this study is to assess the efficacy (decrease in profound fatigue), safety and pharmacokinetics of RSLV-132 in subjects with long Corona Virus (COVID) syndome
What is the current status of trial NCT04944121?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2021-06-25. Estimated completion is 2023-11-30.
What interventions are being tested in trial NCT04944121?
The interventions under investigation include: RSLV-132 (DRUG), Sodium Chloride 0.9% (DRUG).
Who is sponsoring clinical trial NCT04944121?
This trial is sponsored by Resolve Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04944121's enrollment target sits among peer trials
112 631st of 2000 higher than 1,369 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI